• Analysts from UBS, JPMorgan, BofA, and others upgraded multiple stocks, signaling renewed confidence across sectors.
  • Price targets were raised for most names, with notable exceptions like Intuitive Surgical seeing a target cut despite a Buy rating.
  • The upgrades span healthcare, industrials, and energy, reflecting a broader market rotation into quality growth.

A flurry of analyst upgrades hit the tape on Thursday, with UBS, JPMorgan, BofA Global Research, and several other firms raising ratings on a diverse set of stocks. The moves suggest brokers are increasingly bullish on the earnings outlook for names from medical devices to battery technology, even as some target revisions were mixed.

UBS upgraded Edwards Lifesciences (EW) to Buy with a $110 price target, up from $90. The brokerage also lifted Enovix (ENOV) to Buy, setting a target of $51, up from $50. In medtech, UBS boosted Intuitive Surgical (ISRG) to Buy despite trimming its target to $500 from $550, and Stryker (SYK) to Buy with a $400 target, up from $380. The target cut for ISRG, a rare exception, did not dampen the overall optimistic tone.

BofA Global Research upgraded Honeywell (HON) to Neutral from Underperform, raising its target to $265 from $205. JPMorgan upgraded International Paper (IP) to Overweight, lifting its target to $61 from $51. Truist Securities upgraded MGY to Buy with a $33 target, up from $32. Exane BNP Paribas upgraded Nutrien (NTR) to Outperform, while Wells Fargo initiated coverage on QXO with an Overweight rating and $18 target.

Leerink Partners upgraded Gossamer Bio (GOSS) to Outperform, reflecting optimism in the biotech sector. The upgrades span healthcare, industrials, and materials, suggesting a broad-based improvement in analyst sentiment. “These upgrades signal that earnings visibility is improving across sectors, from medical devices to industrial conglomerates,” said a market strategist who declined to be named.

The moves come amid a backdrop of moderate inflation and expectations of rate normalization, with investors rotating into quality growth names. For healthcare, procedure volume rebounds and favorable reimbursement trends are tailwinds; for industrials, capital expenditure cycles and automation demand are supporting upgrades. Battery technology and energy storage names like Enovix benefit from EV supply chain normalization.

While upgrades typically boost short-term momentum, the long-term trajectory will depend on execution. Analysts will be watching upcoming earnings and product milestones for validation. We reached out to the companies for comment but did not receive an immediate response.

Correction: An earlier version of this article misstated the previous price target for MGY. It was $32, not $31.